Sonic Healthcare Limited (ASX:SHL) provides pathology, laboratory and radiology services across Australia, Europe, the United States and the United Kingdom. FY26 delivered higher revenue, EBITDA and profit, with Acquisition activity contributing materially to growth. At the same time, margins were lower in several divisions, leaving integration benefits, cost initiatives and regional operating performance central to the FY27 outlook.

Revenue Rises to A$10.87 Billion

Sonic reported FY26 Revenue of A$10.867 billion, up 12.7% from the prior year.

Organic revenue growth was approximately 5%, with the balance supported by acquisitions and currency movements.

Underlying EBITDA increased 10.6% to A$1.933 billion and finished within the company’s guidance range.

Underlying NPAT increased 17.0% to A$621.0 million.

Underlying EPS Increases to 125.6 Cents

Underlying Diluted Earnings per Share reached 125.6 cents, up 13.9%.

Statutory NPAT attributable to shareholders was A$608.3 million, up 18.4%.

The difference between statutory and Underlying Profit reflects non-recurring items including the Brisbane property transaction and the US debtor adjustment.

Cash generated from operations increased 8.4% to A$1.405 billion.

Margins Ease as Revenue Grows Faster Than EBITDA

Underlying EBITDA growth of 10.6% was below revenue growth of 12.7%.

Sonic identified lower margins in the US, UK and Radiology businesses.

Germany excluding LADR and Switzerland recorded Margin expansion, while Australian Pathology and Belgium broadly maintained margins.

The FY27 earnings outcome will therefore depend partly on whether improvement initiatives offset pressure in the lower-margin regions.

LADR Expands Sonic’s German Operations

The acquisition of LADR became effective on 1 July 2025 and materially increased Sonic’s German scale.

Germany generated FY26 revenue of A$2.729 billion, with statutory growth of 43% and organic constant-currency growth of 5%.

Sonic completed laboratory consolidation, procurement migration, referral insourcing and shared-services integration during the year.

LADR Synergies Continue

More than 40% of total expected LADR synergies were realised during the first year.

The remaining benefits are expected to be captured over the next two financial years.

Integration activity includes laboratory mergers, procurement changes, logistics, IT systems and specialised testing referrals.

Further synergy delivery remains one of the main contributors expected from the acquisition in FY27 and FY28.

Australian Pathology Records Organic Growth

Australian Pathology revenue was A$2.184 billion.

Organic growth was approximately 5%, supported by specialist referrals, private billing and new hospital contracts.

Medicare indexation of 2.4% applied from July 2025, with 2.6% indexation applying from July 2026 to relevant services.

Sonic is also progressing its Docklands laboratory, which is scheduled to open in mid-2027.

US Business Remains Under Review

US revenue was A$2.048 billion in FY26.

Organic growth was limited and margins were lower, prompting Sonic to continue its operating review.

Initiatives include rationalisation of anatomical pathology practices, procurement savings, centralisation of corporate functions and a 10% reduction in corporate headcount across central support functions.

Sonic expects these initiatives to add approximately A$25–30 million to FY27 earnings.

US Debtor Adjustment Affects Statutory Results

Sonic recorded a A$33.0 million pre-tax debtor adjustment relating to revenue recognised in FY24 and FY25.

The adjustment had a A$24.6 million negative impact on NPAT after tax.

The item was treated as non-recurring and excluded from underlying earnings.

US profitability and return on invested Capital remain key areas for management attention in FY27.

UK Revenue Grows but Margin Remains Lower

UK revenue increased 16% to A$926 million, with organic constant-currency growth of 17%.

The Hertfordshire and West Essex NHS outsourcing contract contributed to revenue growth but remained margin dilutive.

Transfer of testing volumes to the Watford hub laboratory was delayed because of NHS operational issues, postponing synergy realisation.

Sonic now expects planned contract margins to be reached by H2 FY28.

Labour Costs Add UK Pressure

The UK business also experienced higher labour costs following a new pay framework introduced during H2 FY26.

These costs will annualise during FY27.

Sonic’s focus is therefore on operating efficiencies, Volume migration and revenue growth while the HWE contract progresses toward planned economics.

The company continues pursuing both public and private diagnostic opportunities in the UK.

Radiology Revenue Reaches A$1.04 Billion

Radiology revenue reached A$1.037 billion, with organic growth of 7%.

Underlying EBITDA increased 5%, meaning the margin was lower than the prior year.

Sonic attributed the pressure to recently opened greenfield sites and changes affecting MRI activity.

Ten greenfield locations have opened over the past two years and are expected to become earnings accretive after their initial ramp-up periods.

Brisbane Laboratory Sale Generates A$445 Million

Sonic completed the sale and leaseback of its Brisbane hub laboratory in June 2026 for A$445 million.

The transaction generated a A$106.7 million accounting gain before tax.

Because accumulated capital losses were available, the transaction produced an A$19.9 million tax benefit and a net A$126.6 million positive NPAT impact.

The gain was excluded from underlying EBITDA guidance.

Debt Increases Following Acquisitions

Net interest-bearing Debt increased to A$3.069 billion from A$2.818 billion.

The increase mainly reflected the LADR and Cairo Diagnostics acquisitions, partly offset by proceeds from the Brisbane property transaction.

Debt cover was 2.2 times, below the covenant ceiling of 3.5 times, while Interest Cover was 10.0 times.

Available cash and undrawn facilities were approximately A$1.6 billion.

Dividend Reaches A$1.08 Per Share

Sonic declared a final Dividend of 63 cents per share, unchanged from FY25.

Together with the 45-cent interim dividend, total FY26 dividends were A$1.08 per share, up from A$1.07.

The final dividend was franked to 60%.

Sonic’s medium-term capital-management framework targets a dividend Payout Ratio of 70%–80% of net profit.

FY27 EBITDA Guidance Is A$1.95–2.03 Billion

Sonic expects FY27 EBITDA of between A$1.950 billion and A$2.030 billion at constant currency.

The guidance excludes approximately A$30 million of back-office IT transformation costs and assumes no future regulatory changes beyond those already known.

Swiss reimbursement changes and the longer HWE integration timetable are expected to affect EBITDA growth.

Acquisition synergies and US cost initiatives are expected to provide offsets.

Technology Investment Continues

Sonic plans to invest approximately A$30 million annually for three years in modernising finance, supply-chain and human-resources systems.

The program also includes automation and selected AI-enabled tools across pathology and radiology workflows.

These investments create near-term costs but are intended to support operating efficiency and scalability across the enlarged group.

Key Risks and Areas to Watch

Regulatory fee changes, particularly in Switzerland and potentially the US, can affect revenue and margins.

Labour costs, acquisition integration and currency movements are additional considerations.

The US operating review, UK HWE integration, LADR synergy delivery, refinancing requirements and FY27 EBITDA performance will remain important measures of progress.